Drug Combination Details
| General Information of the Combination (ID: C57395) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
|
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
EGCG increases the sensitization of cisplatin to cervical cancer cells by inhibiting cell survival and inducing apoptosis. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | microRNA 98 | Molecule Info | ||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| LTEP-a2 | CVCL_6929 | Non-small cell lung cancer | Homo sapiens | |||
| In-vivo Model | A549 cells (5*106) were injected into the dorsal of the female BALB/c nude mice (3-4 week old). | |||||
| Experimental
Result(s) |
EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | SLC31A1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| HEK293T | CVCL_0063 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin Influx transporter CTR1 in ovary cancer. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | The mouse strain C57BL/6 of about 8 weeks age with weights of 18-22 g were used in all experiments. | |||||
| Experimental
Result(s) |
Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice. | |||||
| γ. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AXL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | TYRO3 | Molecule Info | |||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Reversal of cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells. | |||||
